ArticleThe Pan African medical journal2026
Lung cancer-associated membranous nephropathy with positive anti-PLA2R autoantibodies: a case report.
Article in The Pan African medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy (MN) is a common cause of idiopathic nephrotic syndrome in adults. The identification of the phospholipase A2 receptor 1 (PLA2R) as a podocyte antigen in adult patients with MN allows clinicians to quickly and accurately diagnose primary MN. Secondary forms associated with malignancy, medications, infection, or autoimmune disease do not generally express anti-PLA2R autoantibodies. We describe a case of a 66-year-old woman who presented with impure nephrotic syndrome, and a renal biopsy showed MN. The diagnosis of secondary MN was initially retained despite positive Anti- PLA2R in light of the discovery of a pulmonary adenocarcinoma. However, nephrotic syndrome persisted after surgical treatment and tumor remission. Remission was only achieved after the use of immunosuppressive therapy. Our case teaches us that even in the presence of an evident etiology for MN, the diagnosis of primary form should always be reconsidered in the absence of remission, especially when anti-PLA2R antibodies are positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.